Contamination Control Strategy: 5 Tests Inspectors Apply Beyond Box-Ticking
Every sterile and non-sterile site now has a contamination control strategy. Since EU GMP Annex 1 made the CCS a formal expectation, few facilities are missing the document. What inspectors find instead is a binder that lists controls without showing they work. The gap between having a contamination control strategy and being able to defend one is where findings now sit. Inspectors have moved past checking that a CCS exists. They apply a practical test: does this strategy demonstrate control, or does it describe an intention. This post sets out the five tests they apply and how to move a CCS from box-ticking to genuine readiness.
Why a Contamination Control Strategy Gets Cited Even When It Exists
The most common finding is not the absence of a CCS. It is a CCS that reads as a summary of existing SOPs rather than a reasoned argument that contamination is controlled. Annex 1 asks for a strategy that identifies sources of contamination, assesses the risk from each, and defines the controls that manage that risk to an acceptable level. When a document cross-references procedures without connecting hazards to controls to evidence, an inspector cannot follow the logic, and neither can the site. A strategy that cannot be followed cannot be defended.
The 5 Tests Inspectors Apply to a Contamination Control Strategy
Inspectors rarely announce these tests, but the questions behind them are consistent. Each one asks the same underlying thing: can you prove control rather than assert it.
Is the strategy owned and alive
Does every hazard trace to a control
Do monitoring and deviations feed back in
Can you show each control works
Does the CCS match the facility as it is today
Here is what each test looks like in practice.
Ownership and lifecycle. Inspectors look for a named owner, a defined review frequency, and evidence the CCS has actually changed in response to events. A strategy last updated on the day it was written, with no revision history tied to deviations or facility changes, signals a document created to satisfy an auditor rather than to manage risk.
Traceability from hazard to control. A defensible CCS maps each contamination source to the specific control that manages it and to the acceptance criteria that define success. When controls are listed without the hazards they address, or hazards are named with no control assigned, the inspector cannot confirm the risk is covered.
A working feedback loop. Environmental monitoring trends, excursions and deviations should visibly feed back into the strategy. Inspectors ask how a recent excursion changed the CCS. If monitoring data lives in one system and the CCS in another with no connection between them, the strategy is static and the site cannot show it is learning from its own data.
Demonstrated control effectiveness. It is not enough to assert that a control exists. The site should be able to show the control performs, through qualification data, trend analysis or challenge testing. Claims of effectiveness with no supporting evidence are among the most cited weaknesses.
Current-state accuracy. The CCS must describe the facility and process as they are today, not as designed years ago. New equipment, changed flows, added products or modified rooms should already be reflected. An inspector who walks the floor and sees a layout the CCS does not describe has found a gap before reading a single procedure.
Moving From Box-Ticking to Readiness
Closing this gap is less about adding pages and more about connecting what already exists. A contamination control strategy becomes inspection-ready when hazards, controls, monitoring and effectiveness evidence sit in one traceable line of reasoning. This is the principle behind Contamination Control by Design, which builds control into the facility and process from the start rather than layering documentation over it afterwards. For sites strengthening an existing programme, a structured contamination control review can find the weak links before an inspector does.
Frequently Asked Questions
What is the difference between having a CCS and passing inspection on it?
Having a CCS means the document exists. Passing inspection means you can show the strategy identifies contamination sources, assigns controls, and proves those controls work using real monitoring and qualification data. Inspectors test the second, not the first.
Does EU Annex 1 require a contamination control strategy?
Yes. EU GMP Annex 1 expects a formal contamination control strategy that assesses contamination risks and defines the controls that manage them across the facility, utilities, process and personnel. It applies most directly to sterile manufacturing, but the principles are widely applied to non-sterile sites as well.
How often should a contamination control strategy be reviewed?
There is no single mandated interval. The strategy should be reviewed on a defined periodic basis and whenever a change, trend, excursion or deviation affects contamination risk. Inspectors look for evidence the CCS has actually been updated in response to events, not just a stated review frequency.
What is the most common contamination control strategy finding?
A strategy that lists controls without demonstrating they are effective. The document reads as a summary of existing procedures rather than a reasoned, evidence-backed argument that contamination is controlled.
Kieran Falvey is Founder and Managing Director of Pharmalliance Consulting Ltd and the creator of Contamination Control by Design (CCbD). He has more than 20 years designing, building and running pharmaceutical facilities worldwide, across FDA, EMA, TGA, PIC/S and Indian FDA (CDSCO) jurisdictions. Global expert in cGMP Compliance, Remediation and Contamination Control, helping Sterile, Non-Sterile, ATMP and Cosmetic companies navigate cGMP compliance issues.
Pharmalliance Consulting is a GMP compliance consultancy serving pharmaceutical, sterile, non-sterile, OSD, ATMP and cosmetic manufacturers in Ireland, the UK, the EU and the US. It helps sites identify and remediate GMP risks across facilities, quality systems and contamination control, aligned with HPRA, MHRA, EMA and FDA expectations, turning findings into defensible, inspection-ready practice.
If your contamination control strategy needs to move from a binder to a defensible, inspection-ready programme, Pharmalliance can help. Talk to us about Contamination Control by Design or a focused GMP risk and readiness review at pharmalliance.ie/contact.
Comments